Safety, Immunogenicity and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People With Diabetes Also Using Insulin Glargine: 12-Month Results From the GEMELLI 1 Trial
Diabetes Technology and Therapeutics - United States
doi 10.1089/dia.2020.0008
Full Text
Open PDFAbstract
Available in full text
Date
March 31, 2020
Authors
Publisher
Mary Ann Liebert Inc